Key points are not available for this paper at this time.
Most genome-wide association studies (GWAS) of serious mental illness (SMI) have been conducted for categorical diagnoses in samples of primarily European ancestry. The portability of findings to non-Europeans, and to SMI-related symptoms/dimensional traits remains uncertain. In a sample of 8,666 SMI cases and controls from the Paisa region of Colombia we show that a primarily European schizophrenia GWAS polygenic risk score (PRS) predicted all SMI diagnoses in this sample, as well as symptoms (assessed in cases only) and traits assessed agnostic to SMI diagnosis: a one SD unit (SDU) increase in this PRS was associated to decreased risk in cases of suicidal thoughts (OR=0.89, 95% confidence interval 0.84-0.94), depressed mood (OR=0.90, 95% confidence interval 0.85-0.95), and increased risk of delusions (OR=1.12, 95% confidence interval 1.06-1.18) and to decreased cognition (in cases and controls) across five distinct domains (average decrease in cognition of 0.065 SDU, p<7e-05). We show that a published European GWAS of cognition predicted levels of executive function (average decrease in cognition of 0.06 SDU per unit increase in PRS, p<2e-04), but not diagnosis or symptoms. Specific loci identified in the SMI GWAS also showed association to multiple diagnoses, symptoms, and cognitive traits in Paisa. The most noteworthy result was for a locus on chromosome 7p22.3, associated in multiple SMI GWAS, that showed association in Paisa to increased risk of bipolar disorder, and to reduced complex cognition and social cognition. Our findings demonstrate wide portability from European GWAS to an admixed American sample, with associations to multiple transdiagnostic phenotypes.
Maya et al. (Wed,) studied this question.